A new clinical trial involving thymosin beta-4 was registered on May 14, 2026. The study, titled "Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction," is listed under identifier NCT07586865 on ClinicalTrials.gov.
The trial is designated as Phase 2 and its current status is not yet recruiting. This means the study has been registered but has not yet begun enrolling participants.
Thymosin beta-4 remains an unapproved compound used only in a research context. No results, efficacy data, or safety findings have been reported for this trial at this stage.
As the study has not started recruitment, no participant outcomes or interim data exist yet. Further updates will depend on the trial's progression through recruitment and subsequent phases.
Readers interested in background on this compound can consult the thymosin beta-4 overview for additional context.